Search Immortality Topics:

Page 11234..1020..»


Category Archives: Global News Feed

Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results

Conference Call and Live Audio Webcast Scheduled for March 26, 2024 Conference Call and Live Audio Webcast Scheduled for March 26, 2024

Here is the original post:
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results

Posted in Global News Feed | Comments Off on Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results

New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

REDWOOD CITY, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), announced additional positive Phase 1b/2a data on briquilimab as a conditioning agent in the treatment of Fanconi Anemia (FA).

Continued here:
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

Posted in Global News Feed | Comments Off on New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

SALT LAKE CITY, March 15, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including (ALS) and multiple sclerosis (MS), today reported the publication of “Protein Corona Composition of Gold Nanocatalysts” in the journal ACS Pharmacology & Translational Science, a journal of the American Chemical Society that publishes innovative and impactful research with translational relevance across a broad spectrum of biological sciences.

The rest is here:
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Posted in Global News Feed | Comments Off on Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Nuvectis Pharma to Present at the 36th Annual Roth Conference

FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 36th Annual Roth Conference.

Here is the original post:
Nuvectis Pharma to Present at the 36th Annual Roth Conference

Posted in Global News Feed | Comments Off on Nuvectis Pharma to Present at the 36th Annual Roth Conference

Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that by decision dated March 11, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price and $2.5 million stockholders’ equity requirements, through May 20, 2024. The Company is considering all available options that may enable it to timely evidence compliance with the continued listing criteria and maintain its listing on Nasdaq; however, there can be no assurance that the Company will be able to do so.

Here is the original post:
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

Posted in Global News Feed | Comments Off on Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024

Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET

Go here to read the rest:
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024

Posted in Global News Feed | Comments Off on Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024